Epsilon Healthcare Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Epsilon Healthcare's earnings have been declining at an average annual rate of -4.2%, while the Pharmaceuticals industry saw earnings growing at 35.6% annually. Revenues have been growing at an average rate of 16.1% per year.

Belangrijke informatie

-4.2%

Groei van de winst

9.1%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie	31.2%
Inkomstengroei	16.1%
Rendement op eigen vermogen	-64.7%
Nettomarge	-82.2%
Laatste winstupdate	30 Jun 2023

Recente prestatie-updates uit het verleden

Recent updates

Opbrengsten en kosten

Hoe Epsilon Healthcare geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

ASX:EPN Opbrengsten, kosten en inkomsten (AUD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven
30 Jun 23	7	-6	5
31 Mar 23	7	-10	6
31 Dec 22	7	-13	6
30 Sep 22	6	-13	7
30 Jun 22	5	-13	7
31 Mar 22	5	-11	8
31 Dec 21	5	-9	10
30 Sep 21	6	-9	11
30 Jun 21	7	-9	12
31 Mar 21	7	-10	11
31 Dec 20	7	-11	11
30 Sep 20	7	-11	11
30 Jun 20	6	-12	11
31 Mar 20	5	-12	10
31 Dec 19	5	-12	10
30 Sep 19	4	-11	9
30 Jun 19	4	-11	9
31 Mar 19	3	-10	9
31 Dec 18	3	-9	8
30 Sep 18	3	-7	7
30 Jun 18	3	-5	6
31 Mar 18	2	-4	5
31 Dec 17	2	-3	3

Kwaliteitswinsten: EPN is currently unprofitable.

Groeiende winstmarge: EPN is currently unprofitable.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: EPN is unprofitable, and losses have increased over the past 5 years at a rate of 4.2% per year.

Versnelling van de groei: Unable to compare EPN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: EPN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.2%).

Rendement op eigen vermogen

Hoge ROE: EPN has a negative Return on Equity (-64.69%), as it is currently unprofitable.

Epsilon Healthcare Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

First half 2023 earnings released: AU$0.002 loss per share (vs AU$0.035 loss in 1H 2022)

Full year 2022 earnings released: AU$0.066 loss per share (vs AU$0.048 loss in FY 2021)

First half 2022 earnings released: AU$0.035 loss per share (vs AU$0.022 loss in 1H 2021)

Full year 2021 earnings released: AU$0.046 loss per share (vs AU$0.066 loss in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

First half 2021 earnings released: AU$0.022 loss per share (vs AU$0.039 loss in 1H 2020)

Recent updates

Epsilon Healthcare Appoints Richard Legge as Company Secretary

Epsilon Healthcare Limited Announces Termination of Xiao (Josh) Cui as Company Secretary

Epsilon Healthcare Receive Notice from Watercrest Asset Management Pty Ltd

Epsilon Healthcare Receive Notice from Watercrest Asset Management Pty Ltd

Epsilon Healthcare Limited Announces Board Appointments

Epsilon Healthcare Limited Announces Terminates Peter Giannopoulos as Chief Executive Officer

Does Epsilon Healthcare (ASX:EPN) Have A Healthy Balance Sheet?

Non-Executive Deputy Chairman recently bought AU$67k worth of stock

First half 2023 earnings released: AU$0.002 loss per share (vs AU$0.035 loss in 1H 2022)

Non-Executive Deputy Chairman recently bought AU$55k worth of stock

Is Epsilon Healthcare (ASX:EPN) Using Too Much Debt?

New minor risk - Share price stability

Epsilon Healthcare Appoints Peter Giannopoulos as Chief Executive Officer, Effective 23 May, 2023

Full year 2022 earnings released: AU$0.066 loss per share (vs AU$0.048 loss in FY 2021)

Epsilon Healthcare Limited Announces Executive Changes

Epsilon Healthcare Limited Appoints Mark Audet as Chief Financial Officer

No independent directors

Epsilon Healthcare Limited Announces Resignation of Simon Rowe as Director

Epsilon Healthcare Limited Announces Board Changes

Epsilon Healthcare Limited Announces Resignation of Nicholas Marshall as Chief Financial Officer

Epsilon Healthcare Limited Announces Executive Changes

First half 2022 earnings released: AU$0.035 loss per share (vs AU$0.022 loss in 1H 2021)

Epsilon Healthcare Limited Announces Resignation of Dr. Rob Jenny as A Director

Epsilon Healthcare Limited Announces Resignation of Jarrod White as Chief Executive Officer

Epsilon Healthcare Limited Appoints Patrick Baiyu Xu as Director

Epsilon Healthcare Limited, Annual General Meeting, May 31, 2022

Epsilon Healthcare Limited announced that it expects to receive AUD 2.1 million in funding

No independent directors

Full year 2021 earnings released: AU$0.046 loss per share (vs AU$0.066 loss in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Epsilon Healthcare Limited announced that it expects to receive AUD 2.898 million in funding from CPS Capital

First half 2021 earnings released: AU$0.022 loss per share (vs AU$0.039 loss in 1H 2020)

We Think Epsilon Healthcare (ASX:EPN) Has A Fair Chunk Of Debt

Epsilon Healthcare Limited (ASX:EPN) entered into binding heads of agreement to acquire AlternaMed Pty Ltd. from Cannvalate PTY LTD for AUD 4.3 million.

First half 2021 earnings released: AU$0.022 loss per share (vs AU$0.039 loss in 1H 2020)

Joint Company Secretary Philip Leighfield has left the company

Is Epsilon Healthcare (ASX:EPN) Weighed On By Its Debt Load?

Tetra Health Partners with Astrid Healthcare to Operates the Astrid Dispensary in South Yarra

Non Executive Director has left the company

Epsilon Healthcare Limited Announces Resignation of Gary Radcliff as Non-Executive Director

Is Epsilon Healthcare (ASX:EPN) Using Too Much Debt?

Full year 2020 earnings released: AU$0.069 loss per share (vs AU$0.088 loss in FY 2019)

THC Global Group Limited announced that it expects to receive AUD 2.75 million in funding

New 90-day high: AU$0.29

THC Global Group Limited Announces CEO Changes

First half earnings released

New 90-day low - AU$0.24

New 90-day low - AU$0.26

THC Global Group Limited (ASX:THC) completed the acqusition of Tetra Pty Ltd from Meta Growth Corp. (TSXV:META) and others.

New 90-day low - AU$0.27

THC Global Group Limited has completed a Follow-on Equity Offering in the amount of AUD 1.535 million.

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden